Bayer stock edges higher as Japan filing and Roundup ruling shape risk view

Bayer stock trades with modest gains on August 28, 2026, as investors weigh a favorable US court ruling on the Roundup settlement and a fresh Kerendia filing in Japan against ongoing litigation and earnings risks.

Bayer AG (DE000BAY0017) stock showed modest gains on August 28, 2026, as investors digested both a favorable US court decision on the company’s Roundup settlement plan and a new regulatory filing for its kidney drug Kerendia in Japan. Market data from Xetra indicated the shares trading higher in the afternoon, giving Bayer a slightly firmer footing ahead of its next earnings update.

Roundup settlement appeal dismissed

A key legal catalyst for Bayer on August 28, 2026, was the dismissal of an appeal against the company’s proposed Roundup class action settlement in the United States. An article from a European business portal reported that plaintiffs seeking to move jurisdiction for the multibillion-dollar settlement to a California court failed in their attempt, as the relevant US appeals court rejected their request on August 28, 2026. This confirmation of the existing legal path removes one potential procedural hurdle for Bayer’s effort to resolve tens of thousands of glyphosate-related claims.

Further detail came from a US news outlet, which noted that the 8th US Circuit Court of Appeals dismissed a challenge brought by a group of plaintiffs opposed to Bayer’s $7.25 billion state court class action settlement designed to resolve Roundup lawsuits. The report emphasized that the appeals court’s decision leaves intact the framework of the settlement process, which is intended to cover a large portion of the outstanding US claims linked to alleged cancer risks from the herbicide.

For investors, the number that stands out in this legal context is the $7.25 billion settlement figure. While the decision does not end litigation risk for Bayer outright, confirmation that the existing settlement structure remains valid can be seen as a step toward greater clarity around future cash outflows and balance sheet impact. The ruling therefore has an indirect bearing on valuation, as it shapes expectations for potential litigation provisions and related costs over the coming years.

Kerendia filing broadens kidney franchise

Alongside the legal news, Bayer highlighted a new regulatory milestone for its kidney drug Kerendia on August 28, 2026. According to a company announcement published that day, Bayer has submitted an application in Japan for an expanded use of Kerendia in the chronic kidney disease therapeutic area. The filing aims to extend the drug’s indication beyond its existing approved use, targeting non-diabetic forms of chronic kidney disease.

A same-day market overview from a financial portal noted that Bayer shares were in positive territory, explicitly citing the Japan filing for Kerendia as one of the day’s focus points for the stock. The report stated that Bayer had formally applied for approval in Japan for Kerendia in non-diabetic chronic kidney disease at 2:07 p.m. local coverage time, signaling the company’s intention to grow its presence in kidney disease treatments in Asia.

For Bayer, expanding Kerendia’s label into non-diabetic chronic kidney disease is strategically important, as it increases the drug’s addressable patient population in a market with significant unmet medical need. While the filing itself does not yet translate into revenue, investors often view such regulatory steps as precursors to future sales growth and margin contributions if approval is secured. The combination of a broader market opportunity and potential premium pricing for innovative therapies can be a meaningful driver of Bayer’s medium-term earnings profile.

Same-day trading: Bayer stock in positive territory

On the trading floor, Bayer shares showed a constructive tone on August 28, 2026. A morning quote snapshot from Xetra reported that the stock was up 1.5 percent at 49.23 EUR at 9:29 a.m. local time, after opening the session at 48.86 EUR. The intraday high reached 49.38 EUR, indicating a clear move above the opening level as the market responded to the mix of legal and regulatory news.

Later in the day, a separate afternoon update from the same market portal indicated that Bayer’s share price had moderated from the morning peak but remained higher than its previous close. At 4:29 p.m. local time on August 28, 2026, the stock was reported at 48.71 EUR, representing a gain of 0.5 percent over the prior reference level. The shift from a 1.5 percent intraday rise to a 0.5 percent gain suggests that while some early enthusiasm cooled, investors still ended the session with a net positive view.

Taken together, these two trading snapshots allow for a quantified comparison of intraday dynamics. From the opening price of 48.86 EUR to the intraday high of 49.38 EUR, Bayer shares added 0.52 EUR, a move of slightly more than 1 percent within the session. The afternoon quote of 48.71 EUR, compared with the morning level of 49.23 EUR, reflects a 0.52 EUR reduction from the earlier high, but still leaves the stock 0.5 percent above the earlier baseline used in the afternoon summary. This pattern of an early push higher followed by partial consolidation is typical for a day when investors reassess new information without driving a dramatic re-rating.

Litigation and earnings expectations

Beyond the day’s headlines, Bayer’s stock is still heavily influenced by expectations for its next earnings release and updated guidance. A recent overview of the company’s trading environment characterized the shares as being in a holding pattern in late August 2026, with investors weighing the latest reported financial results against the potential for further improvement in earnings, progress on litigation resolution, and balance sheet strength. The same commentary highlighted that on days without strong company-specific news, index movements and broader market sentiment exert more influence on short-term price action.

In this context, the $7.25 billion Roundup settlement framework and the Kerendia filing in Japan serve as important building blocks for investors’ medium-term models. The legal resolution helps reduce uncertainty around future cash obligations, while the expansion of Kerendia’s therapeutic footprint may support revenue and margin trajectories in the pharmaceuticals division once approvals and launches follow. As a result, even modest same-day price moves can be seen as incremental adjustments to a larger, litigation-driven valuation narrative.

Current fundamental figures for Bayer’s most recent quarter are not detailed in the day-filtered sources used here, but the company’s earlier communications and financial portal coverage indicate that investors are closely monitoring trends in core earnings, free cash flow, and net debt in light of potential settlement payments. Historical references to prior years’ results are therefore framed primarily as context rather than as the main determinant of today’s trading, with the focus shifting toward how new legal and regulatory events will shape the upcoming guidance cycle.

Kerendia as a representative product

Kerendia, the product at the center of Bayer’s latest Japan filing, is a key representative of the company’s pharmaceuticals portfolio. The drug is designed for patients with chronic kidney disease and addresses complications that can arise alongside cardiovascular risks. By targeting underlying disease mechanisms, Kerendia aims to reduce the progression of kidney damage and related health burdens for qualifying patients.

Bayer’s strategy for Kerendia has emphasized expanding the drug’s indications across different patient groups and regions. The filing in Japan for non-diabetic chronic kidney disease complements existing approvals in other markets and illustrates the company’s push to leverage clinical data into broader regulatory recognition. If the Japanese authorities grant the expanded label, Kerendia could gain access to a larger segment of the country’s chronic kidney disease population, strengthening Bayer’s foothold in the nephrology space.

Bayer shares and investor takeaways

From an investor’s perspective, August 28, 2026, offered two clear data points for Bayer shares: a modest positive price reaction during the Xetra session and concrete progress on both a major US legal case and a strategically important pharmaceutical filing. The combination of a 0.5 percent gain at 48.71 EUR by late afternoon and the earlier 1.5 percent rise to 49.23 EUR underscores that the market was willing to price in a slightly improved risk-reward profile, even if the move was not dramatic.

As of August 28, 2026, Bayer trades on its home market in euros, with intraday dynamics shaped by legal and regulatory headlines as well as general index trends. Investors looking ahead will pay close attention to the timing and content of the next earnings release, where management is expected to provide updated guidance that reflects both the Roundup settlement trajectory and the growth prospects for drugs like Kerendia. Until then, days such as August 28, 2026, where modest gains accompany tangible news on risk and growth drivers, help refine the market’s view of Bayer’s long-term value.

Fact box

Company: Bayer AG
ISIN: DE000BAY0017
Ticker: BAYN
Exchange: Xetra
Sector / Industry: Health Care / Pharmaceuticals and Crop Science
Index membership: DAX